 | • レポートコード：MRC2304J0193 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、220ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査資料によると、世界のT細胞免疫療法市場規模は、2021年4,712.10百万ドルから2022年に5,309.89百万ドルへと拡大、その後2027年までに年平均12.75％成長して9,684.58百万ドルに達する見通しです。本書は、T細胞免疫療法の世界市場を対象とした調査・分析結果を整理したものであり、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、作用機序別分析（能動免疫療法、受動免疫療法）、製品クラス別分析（二重特異性抗体、サイトカイン、モノクローナル抗体、腫瘍溶解性ウイルス療法）、治療種類別分析（CAR-T、TCR、TIL）、疾患別分析（B細胞悪性腫瘍、肝臓がん、前立腺がん、腎細胞がん）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの項目を掲載しています。なお、本書には、Adaptimmune Therapeutics PLC、Apac Biotech、Atara Biotherapeutics, Inc.、Autolus Limited、bluebird bio, Inc.、Bristol-Myers Squibb Company、CARsgen Therapeutics, Ltd、Cellectis SA、Chimera Bioengineering、Dendreon Pharmaceuticals LLCなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のT細胞免疫療法市場規模：作用機序別 - 能動免疫療法の市場規模 - 受動免疫療法の市場規模 ・世界のT細胞免疫療法市場規模：製品クラス別 - 二重特異性抗体の市場規模 - サイトカインの市場規模 - モノクローナル抗体の市場規模 - 腫瘍溶解性ウイルス療法の市場規模 ・世界のT細胞免疫療法市場規模：治療種類別 - CAR-Tの市場規模 - TCRの市場規模 - TILの市場規模 ・世界のT細胞免疫療法市場規模：疾患別 - B細胞悪性腫瘍における市場規模 - 肝臓がんにおける市場規模 - 前立腺がんにおける市場規模 - 腎細胞がんにおける市場規模 ・世界のT細胞免疫療法市場規模：地域別 - 南北アメリカのT細胞免疫療法市場規模 アメリカのT細胞免疫療法市場規模 カナダのT細胞免疫療法市場規模 ブラジルのT細胞免疫療法市場規模 ... - アジア太平洋のT細胞免疫療法市場規模 日本のT細胞免疫療法市場規模 中国のT細胞免疫療法市場規模 インドのT細胞免疫療法市場規模 韓国のT細胞免疫療法市場規模 台湾のT細胞免疫療法市場規模 ... - ヨーロッパ/中東/アフリカのT細胞免疫療法市場規模 イギリスのT細胞免疫療法市場規模 ドイツのT細胞免疫療法市場規模 フランスのT細胞免疫療法市場規模 ロシアのT細胞免疫療法市場規模 ... - その他地域のT細胞免疫療法市場規模 ・競争状況 ・企業情報 |
The Global T-Cell Immunotherapy Market size was estimated at USD 4,712.10 million in 2021 and expected to reach USD 5,309.89 million in 2022, and is projected to grow at a CAGR 12.75% to reach USD 9,684.58 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the T-Cell Immunotherapy to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Mechanism Of Action, the market was studied across Active Immunotherapy and Passive Immunotherapy.
Based on Product Class, the market was studied across Bispecific Antibodies, Cytokines, Monoclonal Antibodies, and Oncolytic Virus Therapy.
Based on Type of Therapy, the market was studied across CAR-T, TCR, and TIL.
Based on Indication, the market was studied across B-cell Malignancies, Liver Cancer, Prostate Cancer, and Renal Cell Carcinoma.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for T-Cell Immunotherapy market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the T-Cell Immunotherapy Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global T-Cell Immunotherapy Market, including Adaptimmune Therapeutics PLC, Apac Biotech, Atara Biotherapeutics, Inc., Autolus Limited, bluebird bio, Inc., Bristol-Myers Squibb Company, CARsgen Therapeutics, Ltd, Cellectis SA, Chimera Bioengineering, Dendreon Pharmaceuticals LLC, Eureka Therapeutics, Inc., Gilead Sciences, Inc., Green Cross Corporation, Innovative Cellular Therapeutics, Iovance Biotherapeutics, Inc., JW CreaGene Co., Ltd., LAVA Therapeutics BV, Lyell Immunopharma, Neogene Therapeutics, NeoTX Therapeutics, Novartis AG, Oxford Vacmedix, Poseida Therapeutics, TScan Therapeutics, Inc., Xenetic Biosciences, and ZIOPHARM Oncology.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global T-Cell Immunotherapy Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global T-Cell Immunotherapy Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global T-Cell Immunotherapy Market?
4. What is the competitive strategic window for opportunities in the Global T-Cell Immunotherapy Market?
5. What are the technology trends and regulatory frameworks in the Global T-Cell Immunotherapy Market?
6. What is the market share of the leading vendors in the Global T-Cell Immunotherapy Market?
7. What modes and strategic moves are considered suitable for entering the Global T-Cell Immunotherapy Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing Prevalence of Cancer and Autoimmune Diseases
5.1.1.2. Use of Cell-Based Targeted Therapies
5.1.1.3. Increasing R&D Supporting T-cell Immunotherapy
5.1.2. Restraints
5.1.2.1. High Cost of Treatment
5.1.3. Opportunities
5.1.3.1. Commercialisation and Funding by Pharmaceutical Companies
5.1.3.2. Attractiveness of Off-the-Shelf Therapies
5.1.4. Challenges
5.1.4.1. Neurologic Toxicities and Cytokine Release Syndrome
5.2. Cumulative Impact of COVID-19
6. T-Cell Immunotherapy Market, by Mechanism Of Action
6.1. Introduction
6.2. Active Immunotherapy
6.3. Passive Immunotherapy
7. T-Cell Immunotherapy Market, by Product Class
7.1. Introduction
7.2. Bispecific Antibodies
7.3. Cytokines
7.4. Monoclonal Antibodies
7.5. Oncolytic Virus Therapy
8. T-Cell Immunotherapy Market, by Type of Therapy
8.1. Introduction
8.2. CAR-T
8.3. TCR
8.4. TIL
9. T-Cell Immunotherapy Market, by Indication
9.1. Introduction
9.2. B-cell Malignancies
9.3. Liver Cancer
9.4. Prostate Cancer
9.5. Renal Cell Carcinoma
10. Americas T-Cell Immunotherapy Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific T-Cell Immunotherapy Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa T-Cell Immunotherapy Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Adaptimmune Therapeutics PLC
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Apac Biotech
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Atara Biotherapeutics, Inc.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Autolus Limited
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. bluebird bio, Inc.
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Bristol-Myers Squibb Company
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. CARsgen Therapeutics, Ltd
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Cellectis SA
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Chimera Bioengineering
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Dendreon Pharmaceuticals LLC
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Eureka Therapeutics, Inc.
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Gilead Sciences, Inc.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Green Cross Corporation
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Innovative Cellular Therapeutics
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Iovance Biotherapeutics, Inc.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. JW CreaGene Co., Ltd.
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. LAVA Therapeutics BV
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Lyell Immunopharma
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Neogene Therapeutics
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. NeoTX Therapeutics
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. Novartis AG
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
14.22. Oxford Vacmedix
14.22.1. Business Overview
14.22.2. Key Executives
14.22.3. Product & Services
14.23. Poseida Therapeutics
14.23.1. Business Overview
14.23.2. Key Executives
14.23.3. Product & Services
14.24. TScan Therapeutics, Inc.
14.24.1. Business Overview
14.24.2. Key Executives
14.24.3. Product & Services
14.25. Xenetic Biosciences
14.25.1. Business Overview
14.25.2. Key Executives
14.25.3. Product & Services
14.26. ZIOPHARM Oncology
14.26.1. Business Overview
14.26.2. Key Executives
14.26.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing